A 10‐year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions

Publisher Website
Google Scholar
Abstract
Background: Drug therapy for Crohn’s disease and ulcerative colitis is based on anti‐inflammatory and immunodulating drugs, nutritional support and surgical resection. Recently, new drugs have been introduced. Aim: To report drug prescriptions, costs and adverse reactions among inflammatory bowel disease patients in Sweden between 1988 and 1997. Methods: Drug use was calculated from the national Diagnosis and therapy survey and drug costs from prescriptions and drug sales. Adverse drug reactions were obtained from the Medical Products Agency’s National Pharmacovigilance system. Results: The annual drug exposure for Crohn’s disease was 0.55 million daily doses per million population, mainly supplementation and aminosalicylic acids. Mesalazine and olsalazine had 61% within this group. For ulcerative colitis patients, drug exposure was 0.61 million daily doses per million per year and aminosalicylic acids fell from 70% to 65%. For inflammatory bowel disease patients, corticosteroids and nutritional supplementation were common. The annual average cost for inflammatory bowel disease drugs was 7.0 million US dollars. Anually, 32 adverse drug reactions were reported, mainly haematological reactions such as agranulocytosis and pancytopenia (60%), followed by skin reactions. Only two deaths were reported. Aminosalicylic acids were the most commonly reported compounds. Conclusions: Drug use for inflammatory bowel disease in the pre‐biologic agent era rested on aminosalicylic acid drugs and corticosteroids with stable levels, proportions and costs. The level of adverse drug reactions was low but haematological reactions support the monitoring of inflammatory bowel disease patients.